United States securities and exchange commission logo





                              November 15, 2022

       Vininder Singh
       Chief Executive Officer
       BullFrog AI Holdings, Inc.
       325 Ellington Blvd., Unit 317
       Gaithersburg, MD 20878

                                                        Re: BullFrog AI
Holdings, Inc.
                                                            Amendment No. 1 to
Registration Statement on Form S-1
                                                            Filed November 7,
2022
                                                            File No. 333-267951

       Dear Vininder Singh:

              We have reviewed your amended registration statement and have the
following
       comment. In our comment, we may ask you to provide us with information
so we may better
       understand your disclosure.

              Please respond to this letter by amending your registration
statement and providing the
       requested information. If you do not believe our comment applies to your
facts and
       circumstances or do not believe an amendment is appropriate, please tell
us why in your
       response.

              After reviewing any amendment to your registration statement and
the information you
       provide in response to this comment, we may have additional comments.
Unless we note
       otherwise, our references to prior comments are to comments in our
November 3, 2022 letter.

       Amendment No. 1 to Registration Statement on Form S-1

       Use of Proceeds, page 23

   1.                                                   We note your revised
disclosure in response to prior comment 5 and reissue in part.
                                                        Please further revise
your Use of Proceeds section to state how far in the development
                                                        process you estimate
the proceeds from this offering will enable you to reach for both
                                                        your Mebendazole and
siRNA drug programs. Please also disclose the dollar amount you
                                                        intend to allocate to
each program separately. With reference the last sentence of Item
                                                        504 of Regulation S-K,
please also revise the risk factor disclosure on page 17 to indicate
                                                        that you have no
current specific plan for a significant portion of the offering proceeds and
                                                        highlight this point in
the Summary risk factor disclosures on page 3.
 Vininder Singh
BullFrog AI Holdings, Inc.
November 15, 2022
Page 2

       You may contact Ibolya Ignat at 202-551-3636 or Angela Connell at
202-551-3426 if you
have questions regarding comments on the financial statements and related
matters. Please
contact Tyler Howes at 202-551-3370 or Joe McCann at 202-551-6262 with any
other questions.



                                                        Sincerely,
FirstName LastNameVininder Singh
                                                        Division of Corporation
Finance
Comapany NameBullFrog AI Holdings, Inc.
                                                        Office of Life Sciences
November 15, 2022 Page 2
cc:       Arthur Marcus, Esq.
FirstName LastName